

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stephen Barry Parker
Date of last notice	13 March 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Held through a UK Individual Savings Account ("ISA") Registered Holder is Barclays Bank PLC
Date of change	5 March 2021
No. of securities held prior to change	Nil
Class	Ordinary shares
Number acquired	282,316
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	£9,999.99

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	282,316 ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If prior written clearance was provided, on what date was this provided?	
---	--

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brett Anthony Mitchell
Date of last notice	12 August 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Brett and Michelle Mitchell <Mitchell Spring Family A/C> Trustee Brett and Michelle Mitchell <Lefthanders Super Fund A/C> Trustee
Date of change	5 March 2021
No. of securities held prior to change	Brett and Michelle Mitchell <Mitchell Spring Family A/C> 22,264,444 Fully Paid Ordinary Shares 3,750,000 Performance Rights 277,777 Listed Options exercisable at \$0.045 each expiring 31 August 2021 Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 8,140,560 Fully Paid Ordinary Shares 3,750,000 Performance Rights 277,777 Listed Options exercisable at \$0.045 each expiring 31 August 2021 Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at \$0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023
Class	Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	Nil
Number disposed	2,500,000
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil - Cancellation of performance rights
No. of securities held after change	<p>Brett and Michelle Mitchell <Mitchell Spring Family A/C> 22,264,444 Fully Paid Ordinary Shares 2,500,000 Performance Rights 277,777 Listed Options exercisable at \$0.045 each expiring 31 August 2021</p> <p>Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 8,140,560 Fully Paid Ordinary Shares 2,500,000 Performance Rights 277,777 Listed Options exercisable at \$0.045 each expiring 31 August 2021</p> <p>Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at \$0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cancellation of performance shares due to performance conditions lapsing.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Roby Reuven Zomer
Date of last notice	12 August 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Chitta Lu Limited (Director and sole shareholder)
Date of change	5 March 2021
No. of securities held prior to change	Chitta Lu Limited 3,000,001 Fully Paid Ordinary Shares 7,500,000 Performance Rights HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares
Class	Performance Rights
Number acquired	Nil
Number disposed	2,500,000 Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash – forfeited due to not meeting performance conditions.
No. of securities held after change	Chitta Lu Limited 3,000,001 Fully Paid Ordinary Shares 5,000,000 Performance Rights HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cancellation of performance rights due to performance conditions lapsing

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.